We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+2.7%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
-$430M
(-22%)
Cap. Flow
-$140M
Cap. Flow
% of AUM
-9.32%
Top 10 Holdings %
Top 10 Hldgs %
47.39%
Holding
116
New
31
Increased
19
Reduced
31
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$31.2M |
| 2 |
Organon & Co
OGN
|
+$23M |
| 3 |
Community Health Systems
CYH
|
+$19.2M |
| 4 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$18.6M |
| 5 |
Ionis Pharmaceuticals
IONS
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$71.3M |
| 2 |
GSK
GSK
|
+$28.4M |
| 3 |
TG Therapeutics
TGTX
|
+$27.2M |
| 4 |
Elevance Health
ELV
|
+$20.5M |
| 5 |
CTLT
CATALENT, INC.
CTLT
|
+$17.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.27% |
| 2 | Miscellaneous | 33.54% |
| 3 | Industrials | 1.14% |
| 4 | Financials | 0.05% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Immunovant
IMVT
$8.51B
| $1.16M | 0.08% |
110,183
-120,000
| -52% | -$1.68M |
|
77
Natera
NTRA
$47B
| $1.06M | 0.07% |
9,314
-48,386
| -84% | -$4.95M |
|
78
Lexicon Pharmaceuticals
LXRX
$1.02B
| $1.05M | 0.07% |
229,289
-181,304
| -44% | -$873K |
|
79
PUT
Korro Bio
KRRO
$190M
| $921K | 0.06% |
1,850
-2,022
| -52% | -$987K |
|
|
FSTX
80
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
| $859K | 0.06% |
+100,000
| New | +$853K |
|
|
HSKA
81
DELISTED
Heska Corp
HSKA
| $784K | 0.05% |
3,412
-7,628
| -69% | -$1.5M |
|
82
The Ensign Group
ENSG
$10.1B
| $778K | 0.05% |
8,973
-19,910
| -69% | -$1.72M |
|
|
GOCO
83
DELISTED
GoHealth
GOCO
| $772K | 0.05% |
4,593
| – | – |
|
84
Repligen
RGEN
$9.95B
| $737K | 0.05% |
3,692
+2,264
| +159% | +$439K |
|
85
PUT
Biogen
BIIB
$32.3B
| $693K | 0.05% |
+2,000
| New | +$606K |
|
|
CCRN
86
DELISTED
Cross Country Healthcare
CCRN
| $509K | 0.03% |
+30,810
| New | +$470K |
|
87
Guardant Health
GH
$21.7B
| $225K | 0.02% |
1,809
-38,438
| -96% | -$5.17M |
|
88
Acadia Pharmaceuticals
ACAD
$5.02B
| – | – |
-420,000
| Closed | -$9.48M |
|
|
AMRN
89
CALL
Amarin Corp
AMRN
$295M
| – | – |
-22,040
| Closed | -$2.74M |
|
|
APLS
90
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-12,900
| Closed | -$554K |
|
91
argenx
ARGX
$64B
| – | – |
-35,886
| Closed | -$9.88M |
|
92
PUT
ARK Genomic Revolution ETF
ARKG
$1.88B
| – | – |
-56,900
| Closed | -$5.05M |
|
93
Becton Dickinson
BDX
$51.6B
| – | – |
-70,093
| Closed | -$16.6M |
|
94
Cabaletta Bio
CABA
$529M
| – | – |
-76,849
| Closed | -$853K |
|
95
Chewy
CHWY
$9.52B
| – | – |
-13,100
| Closed | -$1.11M |
|
96
CALL
Centene
CNC
$32B
| – | – |
-50,000
| Closed | -$3.2M |
|
97
InflaRx
IFRX
$329M
| – | – |
-268,634
| Closed | -$1.05M |
|
|
IMMP
98
Immutep
IMMP
$56.1M
| – | – |
-249,895
| Closed | -$767K |
|
99
Keros Therapeutics
KROS
$219M
| – | – |
-27,631
| Closed | -$1.7M |
|
|
100
CALL
Korro Bio
KRRO
$190M
| – | – |
-200
| Closed | -$94.8M |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
GIA
MFM
Eversept Partners's Q2 2021 Portfolio in Review
As of Q2 2021, Eversept Partners held 116 positions worth $1.5B, down 22% from $1.93B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Eversept Partners withdrew a net $140M in Q2 2021, closing 29 positions and reducing 31 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $71.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 59% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Eversept Partners opened a new position in Bristol-Myers Squibb worth $32M.
- Eversept Partners's largest Q2 2021 buy was Bristol-Myers Squibb: 478,328 shares worth $32M.
- Eversept Partners added most to Community Health Systems in Q2 2021, an estimated $19.2M increase.
- Eversept Partners's biggest Q2 2021 reduction was GSK, cutting an estimated $28.4M.
- Eversept Partners fully exited Alexion Pharmaceuticals in Q2 2021, selling an estimated $71.3M.
- Eversept Partners's ten largest holdings make up 47% of its $1.5B portfolio in Q2 2021.
- Eversept Partners opened 31 new positions and closed 29 in Q2 2021.
- Eversept Partners's portfolio value fell 22% quarter-over-quarter to $1.5B.
Based on Eversept Partners's 13F filing for Q2 2021, filed 16 Aug 2021.